January 25, 2021 – COVID-19
Whenever possible, we want to allow research participants to be vaccinated against COVID-19, if they choose to do so, and minimize any impact on their research participation. To that end, if the research protocol is...
COVID-19 Updates for DF/HCC
The information on this page applies to all research conducted under the Dana-Farber/Harvard Cancer Center.
For additional information please see:
- Guidance from the NCI on COVID-19
- Guidance from the FDA on COVID-19
- Guidance from OHRP on COVID-19
- CTEP Guidance on Capturing COVID-19 Events in CRFs
Please also consult officials at your home institution for specific information about restrictions, guidance, and changes at your institution.
- BIDMC: Please contact the CCTO for specific information.
- DFCI: Research staff employed by DFCI must follow information on the DFCI Online COVID-19 page and specific information for DFCI researchers.
- MGH: Please contact the CCPO for more information.
- Other DF/HCC member institutions should contact their institutional leadership for information specific to your location.
Recent Announcements
-
-
December 14, 2020 – COVID-19
The policy exceptions announced on March 23, 2020 have been extended until June 2021. An updated note to file has been posted.
-
July 31, 2020 – COVID-19
The policy exceptions announced on March 23, 2020 have been extended until at least December 31, 2020. An updated note to file has been posted.
-
July 13, 2020 – COVID-19
Information regarding the use and documentation of electronic informed consents and electronic signatures on informed consents
-
June 08, 2020 – COVID-19
The DF/HCC member institutions are each developing plans to resume clinical research activities. Human subject research activities, regardless of where and how they occur, must be consistent with the currently allowed...
-
April 15, 2020 – COVID-19
Deviations and violations that have the potential to impact patient safety or trial integrity, including eligibility exceptions, require IRB review. Generally, the DFCI IRB will not approve blanket requests to deviate...
-
March 31, 2020 – COVID-19
On March 17, the US Secretary of Health and Human Services issued a declaration to provide liability immunity for activities related to medical countermeasures against COVID-19. As a result, potential research subjects...
-
March 23, 2020 – COVID-19
Please read carefully for information on approved policy exceptions, additional clarifications, and a note-to-file document
-
March 18, 2020 – COVID-19
Clarifications regarding DF/HCC consent requirements for human subject oncology research in response to shared Partner's communications
-
March 14, 2020 – COVID-19
To all staff participating in human subject research at DF/HCC: Below is some additional information to clarify what changes require prospective review and approval by the DFCI IRB in light of the steps we...